Australia's most trusted
source of pharma news
Thursday, 13 November 2025
Posted 12 November 2025 AM
A CRISPR-Cas9 gene-editing therapy has halved LDL cholesterol and triglyceride levels in a first in-human trial, led by Australian researchers.
“Seeing a single-course treatment safely lower both LDL cholesterol and triglycerides is truly unprecedented,” Lead study investigator and Director of the Victorian Heart Institute at Monash University, Professor Stephen Nicholls said.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.